AbCellera Q3: Loss Narrows to $40.8M, $890M Liquidity After $200M Raise
ABCL has more than doubled off its 52-week low of $2.745.
Summary
AbCellera's Q3 loss narrowed to $40.8M from $57.1M on $10.6M of revenue, and the $200M August raise lifted available liquidity to about $890M. ABCL635's positive Phase 2 data now anchors the pipeline, while ABCL575 will not advance past Phase 1.
Key Events · Earnings and Guidance · ABCL
-
Q3 Loss Narrows on Lower Spend
Revenue was $10.6M versus $9.0M a year ago, and net loss fell to $40.8M, or $(0.13) per share, from $57.1M, or $(0.19) per share, as R&D dropped to $43.5M from $55.0M and SG&A to $13.6M from $25.0M.
-
Liquidity Tops $890M After Raise
Cash, equivalents and marketable securities totaled $764.4M at September 30, 2026, and with over $100M of non-dilutive government funding total available liquidity exceeds $890M following the $200M August offering.
-
ABCL635 Phase 2 Data Anchor Pipeline
ABCL635 cut moderate-to-severe VMS frequency 83% versus 33% for placebo at week 4, with a 58% versus 12% severity reduction; late-stage development is expected in 2027, with expansion into breast and prostate cancer treatment-induced VMS.
-
ABCL575 Shelved After Phase 1
The OX40 ligand program met all Phase 1 endpoints with a ~65-day half-life supporting extended dosing, but AbCellera does not plan to develop it past Phase 1.
Analysis · ABCL · Life Sciences
The quarter itself is an improvement, not a transformation: revenue rose to $10.6M from $9.0M while the net loss narrowed to $40.8M from $57.1M as R&D and SG&A spending came down. The balance sheet is the real story — $764.4M in cash and marketable securities at September 30 plus over $100M of non-dilutive government funding gives roughly $890M of available liquidity, enough to fund late-stage development of ABCL635 without returning to equity markets soon. ABCL635 is now the value driver: positive Phase 2 VMS data with an 83% reduction in moderate-to-severe symptom frequency versus 33% for placebo, and management expects to start late-stage development in 2027 plus expand into cancer-treatment-induced hot flashes. The offset is ABCL575: the Phase 1 met all endpoints but the company will not develop it past Phase 1, writing off a pipeline asset investors had been tracking.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABCL was trading at $12.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $2.75 to $15.02. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.